 Proto-Oncogene Proteins c-bcl-2
"Proto-Oncogene Proteins c-bcl-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
| Descriptor ID |
D019253
|
| MeSH Number(s) |
D12.644.360.075.718 D12.776.476.075.718 D12.776.624.664.700.169
|
| Concept/Terms |
Proto-Oncogene Proteins c-bcl-2- Proto-Oncogene Proteins c-bcl-2
- Proto Oncogene Proteins c bcl 2
- c-bcl-2, Proto-Oncogene Proteins
- bcl-2 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, bcl-2
- bcl 2 Proto Oncogene Proteins
- c-bcl-2 Proteins
- c bcl 2 Proteins
B-Cell Leukemia 2 Family Proteins- B-Cell Leukemia 2 Family Proteins
- B Cell Leukemia 2 Family Proteins
- BCL2 Family Proteins
- Family Proteins, BCL2
- Proteins, BCL2 Family
- BCL2 Proteins
- Proteins, BCL2
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-bcl-2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-bcl-2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-bcl-2" by people in this website by year, and whether "Proto-Oncogene Proteins c-bcl-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 3 | 2 | 5 | | 1998 | 2 | 0 | 2 | | 1999 | 0 | 3 | 3 | | 2000 | 2 | 2 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 4 | 5 | 9 | | 2003 | 4 | 4 | 8 | | 2004 | 4 | 3 | 7 | | 2005 | 2 | 5 | 7 | | 2006 | 0 | 9 | 9 | | 2007 | 3 | 7 | 10 | | 2008 | 2 | 5 | 7 | | 2009 | 4 | 5 | 9 | | 2010 | 2 | 3 | 5 | | 2011 | 1 | 2 | 3 | | 2012 | 7 | 1 | 8 | | 2013 | 2 | 3 | 5 | | 2014 | 2 | 4 | 6 | | 2015 | 1 | 4 | 5 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 2 | 3 | | 2018 | 2 | 4 | 6 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-bcl-2" by people in Profiles.
-
Langan RA, Boyken SE, Ng AH, Samson JA, Dods G, Westbrook AM, Nguyen TH, Lajoie MJ, Chen Z, Berger S, Mulligan VK, Dueber JE, Novak WRP, El-Samad H, Baker D. De novo design of bioactive protein switches. Nature. 2019 08; 572(7768):205-210.
-
D'Aguanno S, Valentini E, Tupone MG, Desideri M, Di Martile M, Spagnuolo M, Buglioni S, Ercolani C, Falcone I, De Dominici M, Milella M, Rizzo MG, Calabretta B, Cota C, Anichini A, Trisciuoglio D, Del Bufalo D. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. J Exp Clin Cancer Res. 2018 Nov 19; 37(1):278.
-
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018 12; 24(12):1859-1866.
-
Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2018 11 12; 34(5):724-740.e4.
-
Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, Amato CM, Couts KL, Bemis JGT, Turner JA, Norris DA, Shellman YG. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis. 2018 09 05; 9(9):907.
-
Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Cancer Res. 2018 10 15; 78(20):5793-5807.
-
Sharma P, Pollyea DA. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. Curr Hematol Malig Rep. 2018 08; 13(4):256-264.
-
De Dominici M, Porazzi P, Soliera AR, Mariani SA, Addya S, Fortina P, Peterson LF, Spinelli O, Rambaldi A, Martinelli G, Ferrari A, Iacobucci I, Calabretta B. Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia. Cancer Res. 2018 02 15; 78(4):1097-1109.
-
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017 09 05; 114(36):E7554-E7563.
-
Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18; 8(29):46801-46817.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|